Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs. [Merged to form Nuvelo, Inc.]

Services provided: collateral.